Opus Genetics, Inc. (IRD) stock
Close on Nov 11, 2026Market cap $358.57MP/E –Yield –
Opus Genetics, Inc. saw revenue fall 45.9% to $7.91M over the twelve months to Sep 30, 2026. At the latest close the market valued the company at $358.57M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $358.57M
- P/E ratio
- –
- Price to sales
- 45.31
- Price to book
- 9.33
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $7.91M
- Net income
- -$136.65M
- EPS, diluted
- -$1.56
- Book value per share
- $0.38
- Diluted shares
- 102M
Trading
- Next earnings
- Mar 9, 2027 (estimated, before the open)
- Previous close
- $4.23
- Open
- $4.31
- Day's range
- $4.13 – $4.52
- Volume
- 1,206,852
- Average volume (20 days)
- 1,314,163
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 0.98
- 52-week range
- $1.70 – $7.07
- RSI (14 days)
- 55.5
- Volatility (1 year)
- 81.0%
- Relative volume
- 0.59×
- WACC
- 9.8%
On 2 of our idea lists: Institutions accumulating, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | IRD | S&P 500 | Difference | IRD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -7.3% | -2.4% | −4.9 pts | ||
| 3 months | +11.1% | -1.2% | +12.2 pts | ||
| Year to date | +114.4% | +12.3% | +102.1 pts | ||
| 1 year | +118.8% | +12.4% | +106.3 pts | ||
| 3 years | +52.3% | +78.8% | −26.5 pts | +15.1% | +21.4% |
| 5 years | +8.8% | +75.2% | −66.3 pts | +1.7% | +11.9% |
| 10 years | -94.7% | +311.1% | −405.8 pts | -25.5% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Opus Genetics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Update
- Update
About Opus Genetics
Pharmaceutical Preparations
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company that develops gene therapies and treatments for ophthalmic conditions. The company focuses on addressing inherited retinal diseases that cause severe vision impairment and blindness. Its development pipeline comprises seven adeno-associated virus gene therapy programs, led by candidates designated as OPGx-LCA5 and OPGx-BEST1, alongside programs targeting mutations in RHO, CNGB1, RDH12, NMNAT1, and MERTK. Additionally, the company develops Phentolamine Ophthalmic Solution 0.75%, an approved treatment for pharmacologically induced pupil dilation. Its therapies serve pediatric and adult patients suffering from degenerative eye disorders.
Company profile, executives and historyOpus Genetics stock: common questions
What is Opus Genetics's stock price?
IRD closed at $4.31 on Nov 11, 2026, up 1.89% on the day. Over the past 52 weeks it traded between $1.70 and $7.07.
What is Opus Genetics's market cap?
Opus Genetics was worth $358.57M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is IRD's P/E ratio?
Opus Genetics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.56), so it has no meaningful P/E ratio.
How much revenue does Opus Genetics make?
Opus Genetics reported revenue of $7.91M for the twelve months to Sep 30, 2026, down 45.9% from a year earlier.
Does Opus Genetics pay a dividend?
No. Opus Genetics has not paid a cash dividend over the last twelve months.
When does Opus Genetics report earnings next?
Opus Genetics is expected to report Q4 FY2026 results on Mar 9, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has IRD stock performed over the past year?
Including dividends, IRD returned +118.8% over the past year, against +12.4% for the S&P 500.
How many IRD shares are sold short?
11M shares were sold short at the latest FINRA report, 20.94% of the float, or 8.4 days of average trading volume.
Who are Opus Genetics's competitors?
Companies most similar to Opus Genetics by business, industry and size include TRDA, PGEN, KROS, PTN, QURE.
See a number that looks wrong?